Drug recall · November 9, 2022
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg recall
Why: Presence of Foreign Substance
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India; NDC 62756-970-83
- Lots / codes
Lot #: DNC1129A, Exp 06/2023 Lot #: DNC1740A, Exp 09/2023
- Quantity
- N/A
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Nationwide with the United States
- Initiated
- October 18, 2022 · Voluntary: Firm initiated
- Classified
- October 31, 2022
- Reported
- November 9, 2022
- Ended
- September 7, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine / naloxone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.